Preclinical analyses of lymphoma cells revealed the presence gene amplification of programmed cell death-1 (PD-1) ligand [79], raising the prospect of anti-PD-1 agents as therapeutic agents in HL. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.